Study Comparing Hypofractionated and Standard Chemoradiation Treatments for Uterine Cervix Cancer
Led by Tehran University of Medical Sciences · Updated on 2021-10-12
60
Participants Needed
1
Research Sites
261 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating treatment options for uterine cervix cancer, focusing on comparing a newer hypofractionated chemoradiotherapy approach with the conventional standard treatment. The study aims to find out if the shorter, higher-dose radiation schedule is not worse in terms of clinical response and side effects. This Phase 2 trial involves patients with cervical cancer stages IB to IIIC and is sponsored by Tehran University of Medical Sciences.
Participants are randomly assigned to one of two groups. The experimental group receives external beam radiotherapy EBRT of 40 Gy delivered in 15 sessions over 3 weeks along with three weekly doses of chemotherapy drug cisplatin. The control group receives standard EBRT of 45 Gy in 25 sessions over 5 weeks with five weekly cisplatin doses. After EBRT, all patients undergo high dose rate brachytherapy consisting of 28 Gy over four weekly sessions.
Throughout the study, patients are monitored for early and late side effects based on established criteria at multiple time points up to three years post-treatment. Clinical response is assessed using dynamic contrast-enhanced pelvic MRI at 3 months, 1 year, and 3 years after brachytherapy. The study also tracks progression-free survival, disease-specific survival, and overall survival over five years. Total participation includes treatment and long-term follow-up evaluations.
CONDITIONS
Brief Title
Clinical Response and Toxicity of Hypo-fractionated Chemoradiotherapy in Cervix Cancer
Research Team
K
Kasra Kolahdouzan, M.D.
E
Ebrahim Esmati, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosis of squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix
Cancer stages IB, IIA, IIB, IIIA, IIIB (with hydronephrosis but no kidney function loss), or IIIC1 (with less than 3 lymph nodes under 3 cm and no common iliac chain involvement)
Eligible for definitive chemoradiotherapy followed by brachytherapy
Female patients aged 18 to 85 years
You will not qualify if you...
Creatinine clearance less than 30 ml/min
Histology types other than those specified in inclusion
Need for paraaortic lymph node irradiation
History of inflammatory bowel disease or connective tissue disorders
Previous pelvic radiotherapy
Cancer stage IA or IV
Eastern Cooperative Oncology Group (ECOG) performance status greater than 2
History of previous hysterectomy
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Approximately 8 to 10 weeks depending on group assignment
Participants receive external beam radiotherapy (EBRT) with concurrent weekly chemotherapy followed by high dose rate brachytherapy.
Weekly visits during EBRT and brachytherapy sessions
Follow-up
Duration - Up to 3 years after treatment completion
Participants are monitored for early and late toxicities and clinical response after completion of treatment.
Visits at completion of brachytherapy, and at 3 months, 6 months, 1 year, and 3 years after treatment
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Hypofractionated versus standard chemoradiotherapy in the definitive treatment of uterine cervix cancer: interim results of a randomized controlled clinical trial.